Want to see ABEO full AI Analyst Report?
Top Page
Abeona Therapeutics
(NASDAQ:ABEO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$6.00
▼(-0.83% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial sustainability—large ongoing losses and heavy negative operating/free cash flow—despite modest leverage. The earnings call adds support due to accelerating early commercial traction and the NTAP reimbursement win, but near-term execution risk (manufacturing yield/spec issues and revenue recognition volatility) remains significant. Technicals are mixed, with near-term weakness but some longer-term moving-average support, while valuation is constrained by a negative P/E and no dividend yield.
Positive Factors
Commercial Revenue Growth
Early revenue growth indicates increasing adoption of ZEVASKYN after launch. Continued treatment activity and physician engagement could establish a durable commercial base as more centers reach steady-state operations.
Negative Factors
Persistent Losses and Cash Burn
Large recurring losses and negative cash generation indicate that current revenue does not yet support the cost base. Unless profitability improves, Abeona may remain dependent on external financing, creating dilution and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial Revenue Growth
Early revenue growth indicates increasing adoption of ZEVASKYN after launch. Continued treatment activity and physician engagement could establish a durable commercial base as more centers reach steady-state operations.
Read all positive factors
Abeona Therapeutics (ABEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$348.25M
Dividend YieldN/A
Average Volume (3M)1.40M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth6280.00%
EPS Growth-212.54%
CountryUS
Employees226
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.14
Shares Outstanding57,184,017
10 Day Avg. Volume1,191,231
30 Day Avg. Volume1,402,709
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.50Price Target Upside238.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$54.52M
Abeona Therapeutics Business Overview & Revenue Model
Company Description
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corr...
How the Company Makes Money
null...
Abeona Therapeutics Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call highlights clear commercial progress: 31% quarter-over-quarter revenue growth, expansion to 7 QTCs, 12 patients treated since launch, improved average manufacturing yields in commercial runs, a strong balance sheet ($146.8M) and a significant NTAP reimbursement win that validates the therapy. However, material operational and manufacturing challenges (one low-yield and one out-of-spec batch causing unrevenueed treatments), logistical fragility around the 84-hour shelf life, regulatory work to revisit an assay specification, and continued GAAP losses introduce meaningful near-term execution risk and revenue volatility. Management has implemented clearer reporting metrics and is pursuing operational learnings to mitigate these issues, but variability in site activation and sensitivity to manufacturing yield remain key risks to the revenue ramp.Positive Updates
Quarterly Revenue Growth
Net ZEVASKYN revenue of $11.4M in Q2 2026, a quarter-over-quarter increase of 31% ($2.7M) versus $8.7M in Q1 2026; 5 patients treated in Q2 with revenue recognized for 4 treatments (one low-yield batch not recognized).
Negative Updates
Manufacturing Failures Leading to Lost Revenue
One low-yield commercial batch in Q2 and one out-of-spec batch in Q3 resulted in no revenue recognized for those two treatments despite patients being treated; company absorbs the cost of goods sold for nonbillable runs.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Net ZEVASKYN revenue of $11.4M in Q2 2026, a quarter-over-quarter increase of 31% ($2.7M) versus $8.7M in Q1 2026; 5 patients treated in Q2 with revenue recognized for 4 treatments (one low-yield batch not recognized).
Read all positive updates
Company Guidance
Guidance from the call emphasized that future disclosures will be anchored to completed operational achievements (patients treated in the quarter and net revenue recognized), and management reiterated a near‑term commercial cadence goal of about 1 patient per month per QTC once centers reach steady state; key metrics cited included Q2 net ZEVASKYN revenue of $11.4M (up 31% QoQ from $8.7M), five patients treated in Q2 (revenue recognized for four due to one low‑yield batch), 12 patients treated since launch (5 in Q2 plus 3 in Q3 to date), seven activated QTCs, ~40% of the addressable market with in‑state QTC access, Medicare representing ~10% of payer mix, NTAP granted effective Oct 1, 2026 (FY2027) as 1 of 3 approvals of 15 applicants, commercial manufacturing averaging ~9 sheets per lot (capacity up to 12 sheets) with a <4‑sheet low‑yield threshold that precludes billing, Q2 gross margin ~63% (management targets ~85–90% at full operating capacity), Q2 R&D $5.0M and SG&A $15.8M, net loss $20.2M ($0.35/share) vs $17.1M ($0.30) in Q1, and cash, cash equivalents and short‑term investments of $146.8M as of June 30, 2026.Abeona Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
67
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.52M | 5.82M | 0.00 | 3.50M | 1.41M | 3.00M |
| Gross Profit | 14.45M | 4.29M | -2.91M | 1.90M | 964.00K | 3.00M |
| EBITDA | -71.44M | 78.59M | -56.62M | -50.57M | -34.38M | -76.82M |
| Net Income | -62.89M | 71.18M | -63.73M | -54.19M | -39.70M | -84.94M |
Balance Sheet | ||||||
| Total Assets | 179.51M | 219.57M | 108.93M | 64.00M | 64.21M | 79.59M |
| Cash, Cash Equivalents and Short-Term Investments | 146.83M | 191.40M | 97.72M | 52.23M | 52.15M | 45.02M |
| Total Debt | 19.87M | 24.97M | 23.05M | 5.40M | 7.63M | 9.38M |
| Total Liabilities | 51.45M | 60.35M | 64.90M | 49.18M | 37.45M | 37.22M |
| Stockholders Equity | 128.06M | 159.22M | 44.03M | 14.83M | 26.76M | 42.37M |
Cash Flow | ||||||
| Free Cash Flow | -81.53M | -84.30M | -58.46M | -37.34M | -43.61M | -69.82M |
| Operating Cash Flow | -76.44M | -76.33M | -56.02M | -37.01M | -43.48M | -65.67M |
| Investing Cash Flow | -34.42M | 105.03M | -39.24M | 208.00K | -23.96M | 66.06M |
| Financing Cash Flow | 3.22M | 26.04M | 104.14M | 37.06M | 43.17M | 24.86M |
Abeona Therapeutics Technical Analysis
Neutral
6.05
Price Trends
6.35
Negative
5.89
Positive
5.42
Positive
Market Momentum
-0.09
Positive
43.21
Neutral
18.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Neutral. The current price of 6.05 is below the 20-day moving average (MA) of 6.52, below the 50-day MA of 6.35, and above the 200-day MA of 5.42, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 43.21 is Neutral, neither overbought nor oversold. The STOCH value of 18.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABEO.
Abeona Therapeutics Risk Analysis
Abeona Therapeutics disclosed 59 risk factors in its most recent earnings report. Abeona Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Abeona Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $798.98M | -6.06 | -106.90% | ― | ― | ― | |
53 Neutral | $178.40M | -1.26 | -938.20% | ― | 159.29% | -7.39% | |
52 Neutral | $1.38B | -0.07 | -91.63% | ― | ― | 69.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $348.25M | -5.36 | -41.69% | ― | 6280.00% | -212.54% | |
45 Neutral | $371.13M | -8.62 | 21.48% | ― | ― | 33.25% |
* Healthcare Sector Average
ABEO
Abeona Therapeutics
6.09
-0.92
-13.12%
GALT
Galectin Therapeutics
3.68
-0.32
-8.00%
SLN
Silence Therapeutics
13.27
8.21
162.25%
HUMA
Humacyte
0.64
-0.86
-57.20%
VOR
Vor Biopharma
23.36
-17.84
-43.30%
Abeona Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Abeona Shareholders Back Board, Equity Plan at Meeting
Positive
Jun 12, 2026
At its virtual annual meeting on June 12, 2026, Abeona Therapeutics stockholders elected Keith A. Goldan and Bernhardt G. Zeiher, M.D. as Class 1 directors to serve until the 2029 annual meeting, and approved on an advisory basis the compensation ...
Executive/Board Changes
Abeona Therapeutics announces resignation of board member
Neutral
Jun 12, 2026
On June 11, 2026, Abeona Therapeutics Inc. announced that Board member Michael Amoroso resigned from the company’s Board of Directors, effective immediately, and also stepped down from the Nominating and Corporate Governance Committee. The c...
Business Operations and StrategyRegulatory Filings and Compliance
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
Neutral
Jun 10, 2026
On an unspecified recent date, Abeona Therapeutics Inc. furnished an updated investor presentation in a Current Report on Form 8-K for use in meetings with investors, analysts, and other market participants. The materials were provided as a furnis...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Abeona Advances ABO-701 T-Cell Therapy Toward IND
Positive
Jun 4, 2026
On June 3, 2026, Abeona Therapeutics Inc. held a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration to discuss ABO-701, its recently licensed engineered T-cell therapy targeting Prostate-Specific Membrane Antigen for t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.